Nanotechnology Now - Press Release: Arrowhead to Host Analyst Event in New York to Discuss RNAi-based Hepatitis B Candidate ARC-520 - Live event on March 25 at 12:30-2:00 EST - Audio and slide presentation also available by conference call and webcast

Home > Press > Arrowhead to Host Analyst Event in New York to Discuss RNAi-based Hepatitis B Candidate ARC-520 - Live event on March 25 at 12:30-2:00 EST - Audio and slide presentation also available by conference call and webcast

Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it will host an analyst and investor event on Monday, March 25, from 12:30 to 2:00 p.m. EST in New York City. The company will present an overview of its RNAi-based drug candidate ARC-520 for the treatment of chronic hepatitis B virus (HBV) infection including preclinical data, HBV disease biology, clinical trial strategy and timelines, market opportunity, clinician and patient perspectives, and new data generated from a chimpanzee with chronic HBV infection.

Arrowhead to Host Analyst Event in New York to Discuss RNAi-based Hepatitis B Candidate ARC-520 - Live event on March 25 at 12:30-2:00 EST - Audio and slide presentation also available by conference call and webcast

Pasadena, CA | Posted on March 7th, 2013

Presenters are: Dr. Robert Gish, Chairman of Arrowhead's HBV Clinical Advisory Board; other key opinion leaders from the HBV community; Dr. Chris Anzalone, Arrowhead's President and CEO; and Dr. Bruce Given, Arrowhead's COO and Head of R&D. The presentation will be broadcast live by webcast and conference call, and it will also be archived on the company website.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus infection. The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs.

For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Research
Vince Anzalone
CFA
626-304-3400

The Trout Group, LLC
Lauren Glaser
646-378-2972

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: